Lmr Partners LLP Biocryst Pharmaceuticals Inc Transaction History

Lmr Partners LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $334,536 - $758,112	-42,400 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $809,200 - $1.38 Million	-70,000 Reduced 62.28%	42,400 $689,000
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $708,812 - $980,164	63,400 Added 129.39%	112,400 $1.56 Million
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $696,290 - $864,849	49,000 New	49,000 $704,000

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.43B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.